Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Obesity (Silver Spring). 2016 Nov 3;24(12):2553–2561. doi: 10.1002/oby.21633

Table 3.

Adverse event summary.

Adverse Event Placebo (N=14) Topiramate (N=16)
Amenorrhea 0 (0%) 1 (6.2%)
Concussion 0 (0%) 2 (12.5%)
Dizziness 0 (0%) 1 (6.3%)
Drowsiness 2 (14.3%) 3 (18.8%)
Dysgeusia 0 (0%) 1 (6.2%)
Insomnia 1 (7.1%) 0 (0%)
Mood problems 1 (7.1%) 1 (6.2%)
Paresthesia 0 (0%) 4 (25.0%)
Pharyngitis 2 (14.3%) 1 (6.2%)
Sinusitis 1 (7.1%) 1 (6.2%)
Fever due to pharyngitis 0 (0%) 1 (6.2%)
Tendon injury 0 (0%) 1 (6.2%)
Diarrhea 1 (7.1%) 2 (12.5%)
Nausea 0 (0%) 1 (6.2%)
Vomiting 0 (0%) 1 (6.2%)